Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Journal:

The Lancet

Published:

2025-09-27

DOI:

10.1016/s0140-6736(25)01148-1

Affiliations:

11

Authors:

136

Go to article

Institutions	Authors	Share
Novartis Pharmaceuticals Corporation, United States of America (USA)	4.000000	0.27
Novartis, Switzerland	3.000000	0.20
IRCCS Bambino Gesù Children's Hospital, Italy	1.000000	0.07
Peking University First Hospital, PKUHSC, China	1.000000	0.07
University of Iowa Stead Family Children’s Hospital, UI, United States of America (USA)	1.000000	0.07
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.07
Newcastle University, United Kingdom (UK)	1.000000	0.07
The University of Iowa (UI), United States of America (USA)	1.000000	0.07
IRCCS Mario Negri Institute, Italy	1.000000	0.07
Royal Victoria Infirmary (RVI), NUTH, United Kingdom (UK)	1.000000	0.07

Interested in Immunology?